Clarient Diagnostic Services, Inc., a GE Healthcare company, has launched a next-generation sequencing assay focused on solid tumor targets for use in clinical trials. This assay allows researchers to perform prospective and retrospective analysis to better understand which patients will respond to particular therapies in order to aid early research efforts.   This is the first next-generation sequencing assay launched since GE’s acquisition of SeqWright, Inc., a research lab offering nucleic ac...